6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag?

Authors

  • Cristina Faingold Dr. César Milstein Care Unit; Cardiovascular Institute of Buenos Aires; Faculty of Medicine of the University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v54i3Sup.283

Keywords:

diabetes, cardiovascular risk, drugs

Abstract

6 voices in 10 minutes: Strategies to reduce cardiovascular risk in patients with diabetes mellitus

When do we choose SGLT2i or GLP1ag?

In recent years, there has been a paradigm shift in diabetes’ aims of treatment, going from glycocentricity to assessment of mortality reduction and cardiovascular risk (CVR).

Three different types of diabetes drugs have been subjected to tests for assessing CV results. Most of them were focused on high-risk CV populations and all drugs demonstrated NO risk increase by using them. Some drugs even showed significant benefits and also some unexpected benefits were found, such as renal protection.

Author Biography

Cristina Faingold, Dr. César Milstein Care Unit; Cardiovascular Institute of Buenos Aires; Faculty of Medicine of the University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

Endocrinologist

Downloads

Published

2023-01-10

Issue

Vol. 54 No. 3Sup (2020): September/December 2020

Section

6 voices in 10 minutes part 2

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.